Share
Hi My name is Suhail Hashmi and I am raising funds for my beloved mother, Mumtaz Begum who is suffering from (Metastatic Carcinoma Breast, ER- Negative, PR- Negative, Her2Neu- 3+, Ki67-40 %) Breast Cancer Last Stage and is undergoing treatment at D Mettle Clinique, Super Specialty Polyclinic OPD Care In Gurugram Gurgaon Haryana. The family has done all it can to collect the total amount required for the treatment but ₹5 Lakh more reqired for further Treatment.
Treatment Reqiured and this is the Last Cure Treatment at this Stage
ROCHE COMPANY - PHESGO (PH-Perjeta + Herceptin; ES-Easy; GO- Go) — a fixed dose combination of two monoclonal antibodies in oncology for the treatment of HER-2 positive breast cancer.
PHESGO is a fixed-dose combination of two monoclonal antibodies – Perjeta (Pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous (under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC injection.
ROCHE Injection PHESGO Vial 600mg. ₹2,30,000 / Per Vial Dose.
TREATMENT HISTORY & PROCEDURE DONE
Palliative Therapy complete 12 Cycles of Trastuzumab Herclon + Pertuzumab Perjeta + Phesgo
Palliative Therapy complete 12 Cycles of Trastuzumab Herclon + Pertuzumab Perjeta + Phesgo
- Injection Trastuzumab Herclon : 7 Doses Complete
- Injection Pertuzumab Perjeta : 7 Doses Complete
- Injection Phesgo : 5 Doses Complete
- Palliative Brain Radiotherapy – 0-10+ Fractions Done in ILBS Hospital Vasant Kunj, Delhi
This is the Last Roche Phesgo 600mg/vial Injection Bill
| Cycle No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| Date | 03-12-2021 | 24-12-2021 | 03-02-2022 | 22-02-2022 | 17-03-2022 | 13-04-2022 | 06-05-2022 |
| Trastuzumab (Herclon) | 680 mg | 520 mg | 520 mg | 520 mg | 520 mg | 520 mg | 520 mg |
| Pertuzumab (Perjeta) | 840 mg | 420 mg | 420 mg | 420 mg | 420 mg | 420 mg | 420 mg |
| Cycle No. | 8 | 9 | 10 | 11 | 12 |
| Date | 20-06-2022 | 02-08-2022 | 23-08-2022 | 13-09-2022 | 04-10-2022 |
| Trastuzumab + Pertuzumab PHESGO | 600 mg | 600 mg | 600 mg | 600 mg | 600 mg |
INVESTIGATIONS
- FNAC Left Breast ( J / 2021 / 1766 , 26-09-2021 ) - Invasive ductal ca rcinoma, CODE - V
- PET CT scan whole body ( 22-10-2021 ) - Metabolically active soft tissue lesion involving left breast- primary neoplasm. Metabolically active left axillary , deep pectoral , left supraclavicular and lower cervical lymph nodes and lesions involving liver- Metastasis
- HPE ( 2129675 , 26-10-2021 ) - Invasive Breast Carcinoma , NST , ER- Negative ( 0/8 ) , PR- Negative ( 0/8 ) , Her2Neu Positive ( 3+ ) , Ki67-40 %
- PET CT scan whole body ( 25-05-2022 ) - As compared to previous study dated 22-10-2021 , there is significant interval decrease in in size and metabolic activity of left breast mass and left axillary level I lymph nodal metastases there is complete resolution of left cervical , left axillary level II - III lymph nodes and hypodense lesion in segment V of liver , overall features suggestive of good partial metabolic response
- Brain MRI – Full Brain
.
Palliative Therapy complete 12 Cycles of Trastuzumab (Herclon) + Pertuzumab (Perjeta) + Phesgo (Review in OPD every 21 days with CBC, LFT, KFT for next cycle of Palliative Therapy with Injection Phesgo 600mg/vial.)
We are grateful for your help and wishes.Thank you.
Regardless of how big or small a donation it is, this could go a long way in fulfilling their needs. We request all friends and well-wishers to come forward and kindly contribute Let us come together and help her for a speedy recovery!
“The battle of life can be won with kindness. Show that you care. Donate now.”
